VHH-D9-scTRAIL is based on the single-chain variant of TRAIL first described by Krippner-Heidenreich et al. (2008), with the advantage of including nanobodies to induce a strong and rapid apoptotic response in different tumor models, such as 2D culture and spheroids, involving a human prostate cancer cell line (DU-145) and a pancreatic cancer cell line (Caplan-1) and is more potent than the ScFv version. This evidence concerns the gene TNFSF10 and neoplasm.